Audience
Labs and companies in the drug development industry searching for a virtual drug development engine
About BIOiSIM
BIOiSIMTM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses. Our models are built on data from thousands of compounds across 7 species, leading to robustness rarely seen in the industry. With a focus on human outcomes, the platform has at its core a translatability engine that transforms insights across species. The BIOiSIMTM platform can be used before the preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.
Other Popular Alternatives & Related Software
SYNTHIA Retrosynthesis Software
Expert-coded by chemists and engineered by computer scientists, SYNTHIA™ Retrosynthesis Software enables scientists to quickly find and easily navigate innovative and novel pathways for novel and published target molecules.
Quickly and efficiently scan hundreds of pathways to help you identify the best option according to your needs.
Explore the most cost-effective routes to your target molecules with state of the art visualization and filtering options.
Easily customize search parameters to eliminate or promote reactions, reagents or classes of molecules.
Explore unique and innovative syntheses that may be unknown for building your desired molecule.
Easily generate a list of commercially available starting materials for your synthesis.
Benefit from ISO/IEC 27001 Information Security Certification to guarantee the confidentiality, integrity, and protection of your data.
Learn more
Recursion
Recursion is a TechBio company focused on transforming drug discovery by combining biology, data, and artificial intelligence. Founded over a decade ago, the company pioneered the use of large-scale cellular imaging to train AI models that decode the biological drivers of disease. Recursion’s mission is to deliver better medicines through novel insights and precision design, reducing the high failure rates of traditional drug development. Its proprietary Recursion OS platform integrates massive biological datasets with machine learning to accelerate discovery from target identification to clinical development. The company has built an advanced pipeline of potential first-in-class and best-in-class therapies targeting aggressive cancers and rare diseases. Automated wet labs and robotics enable millions of experiments per week, feeding continuous learning into its AI models.
Learn more
BenevolentAI
BenevolentAI is an AI-enabled drug discovery platform and scientific technology company that unites advanced artificial intelligence, machine learning, and domain-specific science to accelerate the discovery, design, and development of new medicines for complex diseases by making sense of vast, diverse biomedical data and generating actionable scientific insights faster than traditional methods. Its proprietary Benevolent Platform ingests and harmonizes structured and unstructured biomedical information, including literature, genomics, clinical information, and multi-omics data, into a comprehensive knowledge graph, enabling scientists to reason across biological systems, generate hypotheses, predict novel drug targets, and design candidate molecules with higher confidence and lower failure rates.
Learn more
Bruker Drug Discovery
Bringing a new drug into the market, from the first step to the final market introduction, is a time-consuming, highly regulated, and expensive process, which can take a decade or more. Final success crucially depends on the early availability of accurate analytical results, fast enough for taking the right decisions at the beginning of the development and minimizing late attrition rates. Today’s drug development is mainly based on a rational approach where typically establishing the biological target to focus on is the first key step. This target identification requires a deep understanding of the candidates´ properties to identify the most promising ones as quickly and reliable as possible. Once a biological target has been established, finding the most promising lead molecules is often seen as the next challenge. Typically, lead discovery is the identification of potential drug candidates – either small organic molecules or biologic assemblies with therapeutic potential.
Learn more
Integrations
No integrations listed.
Company Information
VERISIMLife
United States
www.verisimlife.com/our-platform/
Videos and Screen Captures
Other Useful Business Software
AI-generated apps that pass security review
Retool lets you generate dashboards, admin panels, and workflows directly on your data. Type something like “Build me a revenue dashboard on my Stripe data” and get a working app with security, permissions, and compliance built in from day one. Whether on our cloud or self-hosted, create the internal software your team needs without compromising enterprise standards or control.
Product Details
Platforms Supported
Cloud
Training
Documentation
Live Online
In Person
Videos
Support
Phone Support
Online
